Core Insights - FMC Corporation reported a loss of $4.52 per share for Q3 2025, a significant decline from earnings of 52 cents in the same quarter last year. Adjusted earnings per share were 89 cents, up from 69 cents year-over-year. Revenues fell to $542 million, down approximately 49% from the previous year [1][9]. Revenue Performance - The decrease in revenues was primarily due to one-time commercial actions in India related to the business's positioning for sale. Excluding these actions, revenues still declined by 10% year-over-year, driven by a 6% decrease in pricing linked to specific "cost-plus" contracts and increased competition affecting core portfolio volumes [2]. Regional Sales Performance - In North America, sales increased by 4% year-over-year to $244 million, driven by price gains in branded products and higher volumes, surpassing the consensus estimate of $225 million [3]. - Latin American sales decreased by 8% year-over-year to $463 million, impacted by generic competition and a decline in branded product prices, missing the consensus estimate of $516 million [4]. - In Asia (excluding India), revenues fell by 47% year-over-year to $99 million due to lower pricing and reduced volumes, missing the consensus estimate of $153 million [4]. - EMEA saw an 11% year-over-year sales increase to $155 million, fueled by significant volume increases in the growth portfolio, although it lagged behind the consensus estimate of $158 million [5]. Financial Overview - At the end of the quarter, FMC had cash and cash equivalents of $497.7 million, with long-term debt amounting to $3,270.5 million [6]. Q4 Guidance - FMC expects Q4 revenues (excluding India) to range between $1.12 billion and $1.22 billion, indicating a 4% decline at the midpoint compared to 2024. Adjusted EBITDA is forecasted between $265 million and $305 million, reflecting a 16% decline at the midpoint. Adjusted earnings per share are projected to be between $1.14 and $1.36, indicating a 30% year-over-year decrease at the midpoint [7]. Stock Performance - FMC's shares have decreased by 53.9% over the past year, contrasting with a 5.8% decline in the industry [8].

Core Insights - FMC Corporation has formed a strategic partnership with Corteva Agriscience to enhance the use of fluindapyr fungicide technology in the U.S. corn and soybean markets, aiming to assist farmers in combating challenging foliar diseases like tar spot and southern rust [1][8] Partnership Details - The agreement entails both companies marketing fluindapyr-based fungicides to corn and soybean growers across the U.S. FMC will continue to sell its Adastrio fungicide and develop additional fluindapyr products, while Corteva plans to launch its fluindapyr-based product at the start of the 2026 growing season, pending EPA registration [2][8] Market Impact - This partnership is expected to extend FMC's fluindapyr technology to a significant portion of the U.S. corn and soybean markets, which encompass approximately 95 million acres and 80 million acres of planted land, respectively, thereby providing farmers with advanced solutions for managing costly diseases and optimizing crop yields [3] Product Efficacy - Fluindapyr, the active ingredient in Adastrio fungicide, offers long-lasting control and effectively targets pathogens resistant to other fungicides. FMC has already introduced fluindapyr-containing products in several countries and plans to expand to additional markets, including Chile, Honduras, India, and Ukraine, subject to regulatory approvals [4] Financial Outlook - FMC has maintained its revenue outlook for 2025 at $4.15-$4.35 billion, with an adjusted EBITDA forecast of $870-$950 million, indicating a 1% increase at the midpoint from the previous year. The adjusted earnings per share outlook remains at $3.26-$3.70, and the free cash flow forecast is set at $200-$400 million [7]